Needham Reiterates Buy on Trevi Therapeutics, Maintains $23 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.2%

Neg 0% Neu 91.2% Pos 0%

Needham analyst Serge Belanger reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $23 price target.

Comments

No comments yet. Be the first!